OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Monday, July 7th LLSR, GOVX, BPWI, AOGN

Jul 07, 2008 (M2 PRESSWIRE via COMTEX) -- LLSR | Quote | Chart | News | PowerRating -- Our Stocks to Watch today include Lantis Laser Inc. (OTC: LLSR), GeoVax Labs Inc. (OTCBB: GOVX), Big Apple Worldwide Inc. (OTC: BPWI), Avalon Oil & Gas Inc. (OTCBB: AOGN)

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

LANTIS LASER INCORPORATED (OTC: LLSR)

Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php

Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm

Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.

LLSR News:

July 2 - Independent Research Shows More Uses for Lantis Laser's OCT Technology

Lantis Laser Inc. (OTC: LLSR | Quote | Chart | News | PowerRating) (www.lantislaser.com), is drawing attention to the increasing applications of Optical Coherence Tomography (OCT).

In a recently published study in Journal of Endodontics (June 2008) by Shemesh H et al at the Academic Center for Dentistry in Amsterdam, Holland, showing OCT application in root canal therapy for detecting root fractures before filling the canal, it was concluded that OCT is a promising method for non-destructive imaging of the root surfaces. Earlier published research by the same group, showed that OCT could detect perforations and other possible defects that could affect a successful outcome of root canal therapy. Dentists have never been able to obtain this information by any other means.

Lantis Laser has exclusive worldwide rights for OCT technology in the $5 Billion dental equipment industry. The technology, which was developed at MIT, is the next generation in medical imaging following the X-ray, ultrasound, and MRI.

Stan Baron, President & CEO of Lantis, commented that, "The more applications OCT can be used for, the more dentists would find it indispensable and this would, of course, accelerate the rate of adoption of Dental OCT and the market penetration."

Lantis is initially targeting its Dental OCT System for use in the early detection of tooth decay, secondary decay under and around fillings, root surface decay and decay under sealants. However many other applications are surfacing that would indicate that Lantis OCT Dental Imaging System would be deployed in a dental office for many more applications than originally envisaged.

Application in orthodontics have been indicated relating to the detection of early demineralization, the precursor to decay, using OCT. Orthodontic treatment requires patient compliance to achieve optimum levels of oral hygiene, particularly around brackets. OCT can detect early demineralization, a sign that the patient may need special attention to ensure that "white spots" on teeth do not detract from successful treatment. A recent publication by Cosmin Sinescu et al in Int. Soc. Opt Eng. ( May 2008) shoed research to using OCT to examined the outcome of different bracket bonding materials and procedures that could affect stability of bracket retention and minimize failures.

Lantis' OCT Dental Imaging System enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.

GEOVAX LABS INCORPORATED (OTCBB: GOVX | Quote | Chart | News | PowerRating) "Up 15.38% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GOVX.php

GeoVax Labs, Inc., a clinical stage biotechnology company, engages in the research and development of human vaccines for diseases caused by human immunodeficiency virus (HIV) and other infectious agents. Its vaccine candidates completed preclinical efficacy testing in non-human primates and a Phase I clinical study in humans. The company was founded in 2001 and is based in Atlanta, Georgia.

GOVX News:

July 7 - GeoVax Reports Progress on Its AIDS Vaccine Technology

GeoVax Labs, Inc. (OTCBB: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, provided an operational update on the company's progress towards entering Phase 2 preventative human clinical trial testing and plans to proceed into therapeutic human trials with its AIDS vaccine. Five successful human trials evaluating GeoVax AIDS vaccines have previously been reported.

Planned Phase 2 Human Clinical Trial for Prevention of AIDS:

The Company's Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH) supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to start early this fall, subject to FDA approval.

Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic Human Clinical Trials in Planning Stages:

GeoVax also announced summary data from a pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the SIV prototype for the GeoVax AIDS vaccine. In this small pilot study, conducted by Dr. Amara at Emory University, two non-human primates were infected with SIV. At 12 weeks post SIV infection, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment was stopped and the animals were monitored to determine whether the vaccine could control the SIV infection during the absence of the drugs.

The outstanding results from the study revealed the vaccine controlling the infection in the absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The excellent control of the virus infection in the absence of drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV infections.

Based on these excellent results, planning for a therapeutic trial in infected and drug treated humans has been initiated. The intent of therapeutic vaccination is for the vaccine to "control" HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS. Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in the use of costly anti-HIV medications and their often harmful side effects.

Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, "I had not anticipated the extent of vaccine control that was achieved in the already infected non-human primates. These are highly promising results that need to be extended into infected humans to see if the vaccine can be used to reduce the need for taking drugs. The results also warrant more extended studies in already infected non-human primates to explore parameters that both limit and enhance the ability for a vaccine to displace the need for drugs."

Dr. Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized, "It is noteworthy to mention that the GeoVax AIDS vaccines being tested in the preclinical therapeutic trial is the same basic vaccine administered in the Company's human trials testing for a preventative use of the vaccine, vaccinating people before infection to prevent the development of AIDS should they become infected. Thus, a "one for two" vaccine could be a breakthrough solution for the company and the world, saving millions of dollars in redundant development costs and years of testing time by utilizing safety data already achieved in Phase 1 preventative human trials. More important, time to market could be significantly reduced, saving lives much sooner than otherwise."

Further, GeoVax's management is pleased to report that the company is currently engaged in negotiations with a NIH sponsored trial network to administer, conduct and co-sponsor GeoVax's Therapeutic human trial program. Management expects to receive approval for undertaking formal protocol development in the near future and will report more detailed plans accordingly.

"From an operational standpoint, we are very pleased with the overall progress of the company," stated Dr. Robert McNally. "Progress with ongoing preventative vaccine trials and now the potential to address therapeutic use of the vaccine gives GeoVax an expanding role in the fight to control AIDS."

BIG APPLE WORLDWIDE INCORPORATED (OTC: BPWI | Quote | Chart | News | PowerRating) "Up 23.08% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BPWI.php

Big Apple Worldwide, Inc., through its wholly owned subsidiary, Big Apple Wallcovering, Inc., engages in the design and manufacture of architectural wallcovering and fabrics for hospitality, private offices, and commercial interiors in the United States. The company offers fine commercial vinyl wallcovering, as well as provides digital printing services. It supplies its product for various types of commercial projects, such as hotels and motels, restaurants, country clubs, health care facilities, hospitals, banks, casinos, stores, and office buildings. The company's another subsidiary, Elabrient Surfaces, LLC, operates as a commercial interior design development and manufacturing company specializing in commercial wallcovering. Big Apple Worldwide, through its wholly owned subsidiary, Big Apple Travel, Inc., serves as a travel agency and features a travel salon in Orlando, Florida. The company is headquartered in Longwood, Florida.

BPWI News:

July 7 - Big Apple Worldwide Targets All Retail Segments to License New Kiosk Technology

Big Apple Worldwide, Inc. (OTC: BPWI | Quote | Chart | News | PowerRating) announced that the Company's wholly owned subsidiary, Big Apple Wallcovering, has completed and tested the newest version of its proprietary "No More Books " software for use in e-commerce and retail sales. The new version puts the Company in a position to market the technology to retail outlets to sell all kinds of products through space saving kiosks in retail stores, as well as online venues.

Licenses of the upgraded "No More Books " technology are being marketed to other home decor manufacturers and resellers, as well as retailers in other industries. The new version has been modified to improve the shopping cart operation, make more products available through an easier and more powerful search engine, and incorporate a whole new look to the shopping experience, including a tutorial video.

The "No More Books " kiosk program was initially created to eliminate the need for heavy, expensive sample books that wallcovering manufacturers have used for years. Big Apple Wallcovering has placed the kiosks, which take up only four square feet of space, in retail outlets around the U.S., selling wallcoverings from various manufacturers.

"We see this new technology as a potential revenue generator to drive our company forward. With our many contacts in the retail industry, we foresee a wealth of licensing opportunities with 'No More Books ,'" stated Neal Jablon, President of Big Apple Worldwide, Inc.

AVALON OIL & GAS INCORPORATED (OTCBB: AOGN | Quote | Chart | News | PowerRating) "Up 5.88% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/AOGN.php

Avalon Oil & Gas, Inc. engages in the acquisition of producing oil and gas properties in the United States. It holds 50% working interest in the J.C. Kelly wellbore, a 121.9 acre lease in Wood County, Texas; the E.A. Chance wellbores, a 40 acre lease in Camp County, Texas; 50% working interest in the Dixon Heirs, Deltic Farms and Timber, the Gunn wells, and associated units and leases, in Miller County, Arkansas; 10% working interest in 13 wellbores located in Upshur County, Texas; 25% working interest in a six well production property located in Grant Parish, Louisiana; and 15% working interest in the Janssen prospect in Karnes County, Texas. The company also holds 20% interest in the Talora Block and 15% interest in the Mecaya Block. Avalon Oil & Gas, through its subsidiaries, owns licenses for the mitigation of paraffin wax deposition from crude oil using ultrasonic waves; borehole casing technology; and to a system for determining the presence and location of leaks in underground pipes. Avalon Oil & Gas, Inc. has a strategic alliance with UTEK Corporation to develop a portfolio of new technologies for the oil and gas industry. The company is based in Minneapolis, Minnesota.

AOGN News:

July 3 - Avalon Increases Ownership in the East Chandler Field

Avalon Oil & Gas Inc. (OTCBB: AOGN | Quote | Chart | News | PowerRating) (FWB: A3MA.F) (Avalon) announced it has signed a letter agreement to acquire all of the oil- and gas-producing assets owned by Bedford Energy, Inc. in the East Chandler Field, Lincoln County, Oklahoma. Avalon will increase its current interest in the Grace #2 well and acquire working interests in four other producing wells in the East Chandler Field, the Grace #1, Grace #3, Grace #5A and Grace #6 wells. Avalon initially acquired a working interest in the Grace #2 well in June, 2008.

Avalon is increasing its working interest in the Grace #2 from 2.5% to 7.5%; and increasing its net revenue interest in the Grace #2 to 11.95%. Avalon is also acquiring interests in four additional wells in the East Chandler Field. The company is acquiring a 10% working interest and 13.825% net revenue interest in the Grace #1, Grace #3, Grace #5A and Grace #6 wells. Avalon is also acquiring a salt water disposal well and offset and development acreage in the two quarter sections of the East Chandler Field.

The Grace #2 was completed in the Viola Limestone, and is currently producing 350 MCF of gas per day. The Grace #5A was completed in the Prue Sand with an initial potential of 50 BOPD and 300 MCFPD. The Grace #5, the Grace #1, the Grace #3 and the Grace #6 wells will be completed in the Hunton Lime.

In this transaction, Avalon will acquire total reserves of 90,000 barrels of oil and 559 MMCF of gas.

The Hunton Lime Reserves from the Grace #1, the Grace #3 and the Grace #6 wells are estimated to be 48,000 barrels of oil and 423 MMCF gas. The Upper Red Fork Sand reserves for the Grace #5A are estimated to be 30 MMCF of gas.

Avalon will also be acquiring Prue Sand potential in the Grace #3, Grace #5A and the Grace #6 wells. Estimated Prue Sand reserves for these three wells are 33,000 barrels of oil and 81 MMCF of gas.

"We are extremely pleased with this expansion of our ownership in the Grace #2 and newly acquired interests in the four other producing wells in the East Chandler Field," said Kent Rodriguez, Avalon CEO. "This acquisition will increase our revenues nearly three-fold. Avalon will continue to expand our ownership in these wells in the coming months," he added. The company's growing energy portfolio now includes production assets of 49 producing oil and gas wells in 5 states, and is continuing to expand its capital deployment through acquisitions of high potential oil and gas producing properties in the region.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated two hundred thousand restricted 144 shares from a third party for LLSR advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index